Arnold, Sabine http://orcid.org/0000-0002-3368-1688
Wiese, Antonia
Zaid, Sarah
Correll, Christoph U.
Jaite, Charlotte
Funding for this research was provided by:
Charité - Universitätsmedizin Berlin
Article History
Received: 28 September 2021
Accepted: 26 January 2022
First Online: 28 February 2022
Change Date: 19 May 2022
Change Type: Update
Change Details: Following the original publication of this article, the funding declaration of the article has been corrected with the addition of the following note: Open Access funding enabled and organized by Projekt DEAL.
Declarations
:
: The Charité-Universitaetsmedizin Berlin, Germany, local Ethics Committee approved the retrospective chart review of routinely assessed clinical parameters (approval no. EA2/112/19). All patient data routinely collected and stored in the context of hospital treatment were anonymized for research purposes prior to evaluation. The data has been treated following the Data Protection Act 2017 and the General Data Protection Regulation [CitationRef removed]. For the retrospective chart review, patients' formal consent was not required from the local Ethics Committee of the Charité-Universitaetsmedizin Berlin, Germany.
: For a retrospective chart review based on routinely assessed clinical parameters, patients' consent for publication was not required from the local Ethics Committee of the Charité-Universitaetsmedizin Berlin, Germany.
: The authors SA, AW, SZ, and CJ declare that they have no competing interests. CC has been a consultant and/or advisor to or has received honoraria from: Acadia, Alkermes, Allergan, Angelini, Axsome, Gedeon Richter, IntraCellular Therapies, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedAvante-ProPhase, MedInCell, Medscape, Merck, Mitsubishi Tanabe Pharma, Mylan, Neurocrine, Noven, Otsuka, Pfizer, Recordati, Rovi, Servier, Sumitomo Dainippon, Sunovion, Supernus, Takeda, and Teva. He provided expert testimony for Janssen and Otsuka. He served on a Data Safety Monitoring Board for Lundbeck, Rovi, Supernus, and Teva. He has received grant support from Janssen and Takeda. He is also a stock option holder of LB Pharma.